The bill amends title XIX of the Social Security Act to add whole genome sequencing (WGS) and whole exome sequencing (WES) to the list of services covered under Medicaid’s early and periodic screening, diagnostic, and treatment (EPSDT) benefit for children. It defines WGS/WES to include sequencing and the attendant analysis and reports, allows sequencing in inpatient or outpatient settings, and specifies that testing ordered as a first-tier diagnostic for children suspected of genetic disorders, rare diseases, or unexplained developmental conditions must be covered.
Beyond coverage, the bill requires that states pay for WGS/WES separately (not bundled into other payments), directs the Department of Health and Human Services to convene stakeholders and publish information on payments and utilization, and tasks the Government Accountability Office with studying implementation issues such as prior authorization, genetic counseling workforce and laboratory fee schedule alignment. The amendments take effect January 1, 2027.
At a Glance
What It Does
The legislation inserts a new EPSDT-covered service for children—whole genome and whole exome sequencing—when ordered as a first-tier test for suspected genetic disorders, rare diseases, or unexplained developmental problems. It defines the scope of sequencing to include testing of the child and, when clinically indicated for diagnosis, first-degree relatives, plus downstream analysis and data reporting, and requires states to make separate payments rather than bundling the service.
Who It Affects
State Medicaid agencies, Medicaid managed care plans, children's hospitals and pediatric specialists, clinical laboratories that perform WGS/WES and produce analytic reports, and families of Medicaid-enrolled children with congenital anomalies, global developmental delay, or intellectual disability. It also engages national professional and patient organizations through HHS-led convenings.
Why It Matters
The change creates an explicit federal coverage floor for high-complexity genomic testing in pediatric Medicaid, potentially reducing cost barriers for diagnostic sequencing and shifting billing and reimbursement practices. It also directs federal actors to collect data and recommend fixes for operational barriers—information that could influence state uptake, lab reimbursement norms, and workforce planning for genetic counseling.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill adds a new paragraph to section 1905(r) of the Social Security Act so that whole genome sequencing and whole exome sequencing qualify as covered EPSDT services for children when used as a first-tier diagnostic test. That means if a child on Medicaid is suspected of having a genetic disorder, rare disease, or an unexplained condition such as a congenital anomaly, global developmental delay, or intellectual disability, a physician or other authorized provider can order WGS or WES and expect the procedure and the lab’s analytic report to be covered under Medicaid.
The statutory definition is broader than a narrow lab test: it explicitly covers sequencing of the child’s DNA and, when needed primarily to diagnose or treat the child, sequencing of first-degree biological relatives. It also covers the downstream elements labs deliver—analysis, interpretation, and data reports—so payers are on notice that coverage should include those components, not just raw sequencing data.
The provision applies whether the sequence is done inpatient or outpatient and must be provided when ordered as a first-tier test within the provider’s scope of practice under state law.To protect payment clarity, the bill amends section 1902(a) to require states to make separate payments for WGS/WES rather than bundling costs into broader payments for other services. The Department of Health and Human Services must convene a range of national organizations and stakeholders to identify implementation challenges and best practices, and publish a public report within two years that lists state-by-state payment amounts and counts of children receiving sequencing plus related outcomes and services triggered by sequencing.Finally, the Comptroller General (GAO) must collect stakeholder feedback and assess three implementation pressure points—prior authorization impacts, genetic counselor workforce and reimbursement, and how clinical laboratory fee schedules line up with market costs—and recommend improvements.
The operative date for the statutory changes is January 1, 2027, giving states and providers time to prepare coding, billing, and operational processes.
The Five Things You Need to Know
The bill adds a new EPSDT-covered service: whole genome sequencing and whole exome sequencing when ordered as a first-tier test for a child suspected of a genetic disorder, rare disease, or unexplained developmental condition.
It defines sequencing to include testing of first-degree biological relatives when done primarily to diagnose or treat the child, and to include analysis, interpretation, and the resulting data report.
States must pay for WGS/WES separately under Medicaid (new section 1902(a)(90)), meaning payment cannot be bundled into other medical assistance rates.
HHS must convene national stakeholder groups and publish, within two years, a public report listing state payment amounts, the number of children receiving sequencing, resulting services, and related outcome information.
GAO must collect feedback on implementation and assess prior authorization effects, genetic counselor workforce and reimbursement issues, and alignment between market costs and the Medicare clinical laboratory fee schedule, then make recommendations.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Names the bill the 'Genomic Answers for Children’s Health Act of 2026.' This is a standard heading and has no operative effect beyond identification.
Add WGS/WES to EPSDT-covered services
This provision inserts a new paragraph into section 1905(r) to make WGS and WES a covered component of the EPSDT benefit for children when ordered as a first-tier diagnostic test. It specifies that sequencing may be furnished inpatient or outpatient and must be ordered by a clinician acting within the provider’s state scope of practice. Practically, states must interpret EPSDT rules to include these tests when medically appropriate under the listed clinical triggers (suspected genetic disorder, rare disease, unexplained conditions such as congenital anomalies or developmental delays).
Defines scope of sequencing and reports
The bill defines 'whole genome sequencing and whole exome sequencing' to mean both the laboratory determination of DNA sequence and, where clinically useful for the child, sequencing of first-degree relatives if done primarily for the child’s diagnosis or treatment. It also clarifies that analysis, interpretation, and data reports delivered by labs are part of the covered service, signaling that payers should reimburse for more than raw data production.
Separate payment requirement
By adding a new paragraph to 1902(a), the bill requires that payment for WGS/WES is made separately and not bundled into other medical assistance payments. That changes how states and managed care plans will need to code and reimburse for these services and may require state plan amendments or claims processing updates to create distinct line-item payments.
HHS outreach, public reporting, and GAO study
HHS must convene national organizations (medical societies, hospitals, labs, rare disease and Medicaid groups) to identify implementation challenges and best practices, and conduct outreach so stakeholders know about EPSDT coverage. HHS also must publish a public report within two years with state payment amounts and utilization/outcomes data. Separately, GAO must gather stakeholder feedback and evaluate prior authorization impacts, genetic counselor workforce and reimbursement, and alignment of market costs with Medicare’s clinical laboratory fee schedule, then recommend improvements. These provisions build an information-gathering and guidance layer intended to smooth state implementation.
Effective date
Specifies that the statutory changes apply beginning January 1, 2027, giving states, providers, and laboratories roughly a year to prepare for new coverage and payment rules.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Medicaid-enrolled children with suspected genetic disorders, congenital anomalies, global developmental delay, or intellectual disability — they gain a clearer entitlement to diagnostic sequencing and associated analysis, reducing financial and administrative barriers to testing.
- Families and caregivers of affected children — potentially shorter diagnostic odysseys, earlier diagnoses, and access to condition-specific care or clinical trials that rely on genetic confirmation.
- Clinical laboratories and genomic testing companies — explicit Medicaid coverage and separate payment increase predictable demand and the likelihood of reimbursement for analytic and interpretive services.
- Pediatric specialists and geneticists — clearer billing and coverage rules reduce disputes with payers and may streamline clinical decision-making when sequencing is clinically indicated.
- Children’s hospitals and healthcare systems — incorporation of WGS/WES into EPSDT supports care pathways for complex pediatric patients and may reduce long-term costs associated with undiagnosed conditions.
Who Bears the Cost
- State Medicaid programs — separate payment requirements and expanded utilization can increase program spending and may require state plan amendments and budget adjustments.
- Medicaid managed care organizations — they will face pressure to cover separate payments for sequencing within capitated arrangements or renegotiate rates and carve-outs with states and providers.
- Smaller clinical labs and provider practices — while demand may grow, these entities may need to invest in compliance, billing infrastructure, data reporting, and staffing (including access to genetic counseling) to meet payer documentation expectations.
- HHS and federal audit resources — the department must run convenings and publish a report, and GAO must perform a multi-part study, which imposes administrative and analytic workloads at the federal level.
- Genetic counselors and related workforce — increased utilization highlights existing workforce shortages and creates tension over reimbursement rates and access to appropriately trained personnel.
Key Issues
The Core Tension
The central dilemma is between broadening access to high-value genomic diagnostics for children and containing program costs and inappropriate use: the bill removes a coverage ambiguity to lower financial barriers, but it stops short of clinical guardrails or payment standards, pushing implementation choices—and the trade-offs between access, utilization oversight, and fiscal impact—down to states, payers, and providers.
The bill creates a federal coverage expectation but leaves important implementation details to states and federal agencies. It does not prescribe clinical criteria beyond broad diagnostic triggers (e.g., 'suspected genetic disorder' or 'global developmental delay'), so states and payers will still set detailed prior authorization rules, documentation standards, and medical necessity criteria.
That gap can produce variation in access across states depending on how aggressively state Medicaid programs and managed care plans adopt the language or impose utilization controls.
Mandating separate payment prevents automatic bundling but does not set rates or payment methodology. States could respond with limited payment amounts, narrow prior authorization, or restrictive coding rules to control costs, which risks reintroducing barriers the statute intends to eliminate.
The GAO review and HHS convenings are designed to surface these issues, but their recommendations are nonbinding—so the real-world effect depends on state action, negotiated managed care contracts, and lab rate-setting. Finally, the bill raises workforce and operational challenges: genetic counseling shortages, lab capacity, and the administrative burden of new claims and reporting systems could delay the practical expansion of access even after the statutory effective date.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.